2-(2,4-Dihydroxyphenyl)-5,7-dihydroxy-6,8-bis(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 2-(2,4-Dihydroxyphenyl)-5,7-dihydroxy-6,8-bis(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
• 化学式: C₂₅H₂₈O₆
• 分子量: 424.5
• InChiKey: ZTEYEFPSJPSRRA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  107
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• T-TYPE CALCIUM CHANNEL INHIBITOR
  申请人：KINKI UNIVERSITY

  公开号：US20200308132A1

  公开（公告）日：2020-10-01

  A new analgesic has been developed for T-type calcium channels as therapeutic targets. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1): wherein each of R 1 and R 2 independently represents —H or —OH; R 3 represents —OH; R 4 represents —OH or —H; R 5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms, or a pharmaceutically acceptable salt or solvate thereof. The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.

  已经开发出一种新的镇痛剂，用于T型钙通道作为治疗靶点。本发明提供了一种T型钙通道抑制剂，其化学式表示为（1）：其中R1和R2分别独立表示—H或—OH；R3表示—OH；R4表示—OH或—H；R5表示具有一到十个碳原子的直链或支链烷基或环烷基烷基，或具有两到十个碳原子的直链或支链烯基或环烷基烯基，或其药学上可接受的盐或溶剂。本发明还提供了这种T型钙通道抑制剂，含有T型钙通道抑制剂的药物，以及用于具有有效T型钙通道抑制作用的疾病的治疗或预防剂。
• GENE NETWORK-BASED METHOD FOR CONFIRMING DRUG ACTION
  申请人：Tsinghua University

  公开号：EP2369493A1

  公开（公告）日：2011-09-28

  The invention provides a network-based method for confirming drug action(drug effect, synergistic reaction). The method be carried out by mapping a first drug genes/gene products subset and a second genes/gene products subset in a gene network. The second genes/gene products subset can be a second drug genes/gene products subset or a biological process genes/gene products subset. The invention also provides a tool for pre-clinical drug screening.

  本发明提供了一种基于网络的确认药物作用（药物效应、协同反应）的方法。该方法通过在基因网络中绘制第一药物基因/基因产物子集和第二基因/基因产物子集来实现。第二基因/基因产物子集可以是第二药物基因/基因产物子集，也可以是生物过程基因/基因产物子集。本发明还为临床前药物筛选提供了一种工具。
• AIR FRESHENER COMPOSITION AND PREPARATION METHOD THEREFOR
  申请人：Wang, Jingning

  公开号：EP3388137A1

  公开（公告）日：2018-10-17

  The present invention relates to the field of air cleaning, and specifically discloses an air freshener composition. The air freshener composition comprises component A and component B, wherein a weight ratio of the component A to the component B is 1: 0.5-3; the component A comprises, in parts by weight, 10-30 parts by weight of an active agent; 6-15 parts by weight of a carrier; 1-4 parts by weight of a pH regulator; and 0.01-0.2 part by weight of an antioxidant; the component B is a plant extract solution, wherein the plant extract solution comprises at least, in parts by weight: 5-30 parts by weight of an extract of a mixture of Populus nigra var. italica, grapefruit peels and eucalyptus leaves; 0.1-5 parts by weight of Sophora flavescens extract; 1-3 parts by weight of Aloe vera extract; 1-10 parts by weight of fresh orange peel extract; 0.5-3 parts by weight of Nandina domestica extract; 0.5-10 parts by weight of Eucalyptus robusta Smith extract; 1-8 parts by weight of Robinia pseudoacacia L. extract; 1-5 parts by weight of Chrysanthemum morifolium extract; and 0.1-2 parts by weight of artemisinin.

  本发明涉及空气清洁领域，具体公开了一种空气清新剂组合物。该空气清新剂组合物包括组分 A 和组分 B，其中组分 A 与组分 B 的重量比为 1：0.5-3；组分 A 按重量份数计包括：10-30 份活性剂；6-15 份载体；1-4 份 pH 值调节剂；以及 0.01-0.2 份抗氧化剂；组分 B 为植物提取物溶液，其中植物提取物溶液按重量份数计至少包括：5-30 份黑杨变种、葡萄柚皮和桉树叶的混合物提取物；0.1-5 份桉树叶提取物（按重量份数计）；0.1-0.2 份桉树叶提取物（按重量份数计）；0.1-0.3 份桉树叶提取物（按重量份数计）；0.1-0.4 份桉树叶提取物（按重量份数计）；0.1-0.5 份桉树叶提取物（按重量份数计）。italica、柚子皮和桉树叶的混合物的提取物；0.1-5 份（按重量份数计）白槐提取物；1-3 份（按重量份数计）芦荟提取物；1-10 份（按重量份数计）鲜橙皮提取物；0.5-3 份（按重量份数计）南丹提取物；0.5-10 份（按重量计）桉树提取物；1-8 份（按重量计）洋槐提取物；1-5 份（按重量计）菊花提取物；以及 0.1-2 份（按重量计）青蒿素。
• T-type calcium channel inhibitor
  申请人：KINKI UNIVERSITY

  公开号：US10633358B2

  公开（公告）日：2020-04-28

  The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R1 and R2 independently represents H, —OH or —OR11 wherein R11 represents a C1-3 alkyl group; each of R3 and R4 independently represents H, —OH or —OR12, wherein R12 represents a C1-3 alkyl group; and each of R5 and R6 independently represents H, a halogen atom, a C1-10 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a phenyl group (which may be substituted by a C1-6 alkoxy group or a halogen atom), a —C1-3 alkyl-phenyl group (which may be substituted by a C1-6 alkyloxy group or a halogen atom) or a C10-50 prenyl group.)

  本发明提供了一种 T 型钙通道抑制剂，它是由式（1）代表的化合物、该化合物的药学上可接受的盐或该化合物的溶液。本发明还提供：这种 T 型钙通道抑制剂；含有这种 T 型钙通道抑制剂的药品；以及一种治疗剂或疾病预防剂，其有效作用为 T 型钙通道抑制作用。式（1）中，R1 和 R2 各自独立地代表 H、-OH 或-OR11，其中 R11 代表 C1-3 烷基；R3 和 R4 各自独立地代表 H、-OH 或-OR12，其中 R12 代表 C1-3 烷基；R5和R6各自独立地代表H、卤素原子、C1-10烷基、C2-6烯基、C2-6炔基、苯基（可被C1-6烷氧基或卤素原子取代）、-C1-3烷基苯基（可被C1-6烷氧基或卤素原子取代）或C10-50链烯基。)
• Air freshener composition and preparation method thereof
  申请人：Wang Jingning

  公开号：US10744219B2

  公开（公告）日：2020-08-18

  The present invention relates to the field of air cleaning, and specifically discloses an air freshener composition. The air freshener composition comprises component A and component B, wherein a weight ratio of the component A to the component B is 1:0.5-3; the component A comprises, in parts by weight, 10-30 parts by weight of an active agent; 6-15 parts by weight of a carrier; 1-4 parts by weight of a pH regulator; and 0.01-0.2 part by weight of an antioxidant; the component B is a plant extract solution, wherein the plant extract solution comprises at least, in parts by weight: 5-30 parts by weight of an extract of a mixture of Populus nigra var. italica, grapefruit peels and eucalyptus leaves; 0.1-5 parts by weight of Sophora flavescens extract; 1-3 parts by weight of Aloe vera extract; 1-10 parts by weight of fresh orange peel extract; 0.5-3 parts by weight of Nandina domestica extract; 0.5-10 parts by weight of Eucalyptus robusta Smith extract; 1-8 parts by weight of Robinia pseudoacacia L. extract; 1-5 parts by weight of Chrysanthemum morifolium extract; and 0.1-2 parts by weight of artemisinin.

  本发明涉及空气净化领域，具体公开了一种空气清新剂组合物。该空气清新剂组合物由组分 A 和组分 B 组成，其中组分 A 与组分 B 的重量比为 1:0.5-3；组分 A 按重量份数计包括：10-30 份活性剂；6-15 份载体；1-4 份 pH 值调节剂；以及 0.01-0.2 份抗氧化剂；组分 B 为植物提取物溶液，其中植物提取物溶液按重量份数计至少包括：5-30 份黑杨变种、柚子皮和桉树叶的混合物提取物；0.1-5 份桉树叶提取物（按重量份数计）；0.1-0.2 份桉树叶提取物（按重量份数计）；0.1-0.3 份桉树叶提取物（按重量份数计）；0.1-0.4 份桉树叶提取物（按重量份数计）；0.1-0.5 份桉树叶提取物（按重量份数计）。italica、柚子皮和桉树叶的混合物的提取物；0.1-5 份（按重量份数计）白槐提取物；1-3 份（按重量份数计）芦荟提取物；1-10 份（按重量份数计）鲜橙皮提取物；0.5-3 份（按重量份数计）南丹提取物；0.5-10 份（按重量计）桉树提取物；1-8 份（按重量计）洋槐提取物；1-5 份（按重量计）菊花提取物；以及 0.1-2 份（按重量计）青蒿素。